BiotechTube
Richter BioLogics

Richter BioLogics

Hamburg, Germany· Est.
richterbiologics.eu
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Richter BioLogics is a leading European CDMO focused exclusively on microbial expression systems for biologics manufacturing. With a strong track record and facilities approved by major regulatory bodies like the FDA and EMA, it provides flexible, scalable production from process development to GMP manufacturing. The company caters to a diverse customer base, from large pharma to biotech, and is positioned in the high-growth biologics CDMO market, though it faces competition and is dependent on client project flow.

BiologicsAntibodies

Technology Platform

Specialized in microbial (E. coli and Pichia pastoris) fermentation and downstream processing for the production of recombinant proteins, peptides, antibody fragments (VHH/Nanobodies, Fab), plasmid DNA, and bacterial vaccines.

Opportunities

Growing demand for plasmid DNA for gene/cell therapies and mRNA vaccines, and increasing adoption of single-domain antibodies and fragments, both efficiently produced in microbial systems.
The trend towards outsourcing by biotechs and need for EU-based manufacturing for supply chain resilience present significant growth avenues.

Risk Factors

Revenue is project-dependent and susceptible to client attrition or pipeline failures.
Intense competition from larger, diversified CDMOs and other microbial specialists could pressure margins.
Regulatory non-compliance or a significant quality incident at a facility could severely damage reputation and business.

Competitive Landscape

Richter BioLogics competes in the microbial biologics CDMO segment against other specialized firms like BioNTech's plasmid DNA arm (formerly JPT Peptide Technologies), Lonza's microbial network (though larger), and Fujifilm Diosynth Biotechnologies. Its differentiation lies in its focused European footprint, deep expertise in both E. coli and Pichia, and end-to-end service model for niche modalities like bacterial vaccines and antibody fragments.

More companies in Biologics / Biosimilars →More companies in Germany →